A lack of innovation in prosthetics in recent decades means opportunity for Halifax start-up Awenza Health Inc. Founded two years ago, the company is working to disrupt the prosthetics market and provide better solutions for patients through new technologies.
Many current products on the market, says CEO Sam Awara, cause high levels of discomfort and even pain in some situations. So Awenza is building a suite of products to solve these issues for those with limb differences.
Karina Gasbarrino uses AI to tackle the second-leading cause of death and third-leading cause of disability worldwide – stroke. Her journey started more than a decade ago when she lost her grandfather to a sudden stroke. Since then, she has devoted her academic career to his memory, helping to advance early detection and diagnosis of harmful fatty deposits in the arteries of the neck. Rupturing of these plaques is the main cause of strokes.
Structural Genomics Consortium (SGC), the Canadian-led consortium of pharmaceutical companies, clinicians and academia, supports open-access drug discovery around the world. And it’s bringing hope to the 300 million people afflicted by rare diseases and a world ravaged by COVID-19.
For Toronto-based Dose Biosystems, a focus on researching and developing the next generation of probiotics brings a hiring challenge: finding and onboarding highly specialized talent. Coming directly from doctoral programs, new employees encounter an unfamiliar environment that requires new skills and different ways of working.
When the COVID-19 pandemic was announced and the Government of Canada called upon researchers and businesses to develop solutions, Ramtin Rasoulinezhad answered.
A graduate student at Western University, Ramtin was working as a research engineer supported by Mitacs Accelerate . He was working on the Net Zero Energy Building project with AVL Manufacturing when CEO Vince Discristofaro selected him to work directly with the Hybrid Solution Division.
Join a thriving innovation ecosystem. Subscribe now